Dr. Agarwal's Health Care Limited will host an earnings and analyst conference call on August 04, 2026, at 05:30 PM IST to discuss its financial performance for the quarter ended June 30, 2026. The company’s Board of Directors is scheduled to meet on the same day to consider and approve the unaudited standalone and consolidated financial results for the period. Investors seeking insights into the company’s latest operational and financial metrics should note that the trading window remains closed until 48 hours after the announcement of these results, as per the company’s Code of Conduct for Prevention of Insider Trading.

The conference call is scheduled from 05:30 PM to 06:30 PM IST. Dr. Adil Agarwal, Whole-time Director and Chief Executive Officer, Mr. Yashwanth Venkat, Chief Financial Officer, and Ms. Aashna Dharia, Head of Investor Relations, will represent the company during the discussion. The event aims to provide clarity on the financial outcomes for the first quarter of FY27.

Conference Call Details

Participants can join the call via dial-in numbers provided for domestic and international attendees. The company has issued reference AHCL/2026-27/C030 in compliance with Regulation 29 and 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dial-in Information

An express join link via Diamond Pass is also available for registered participants. Attendees are requested to dial in ten minutes before the scheduled start time.

Regulatory Compliance

The intimation was signed by Thanikainathan Arumugam, Company Secretary and Compliance Officer, on July 28, 2026. The information has been published on the company’s website and submitted to both BSE Limited and National Stock Exchange of India Limited. The trading window closure ensures equitable information distribution among shareholders ahead of the public disclosure of the quarterly results.

Dr. Agarwal's Health Care Limited has announced that the National Company Law Tribunal (NCLT), Chennai Bench, will hear its petition for a scheme of amalgamation with Dr. Agarwal's Eye Hospital Limited on August 19, 2026. The joint petition was presented under Sections 230 to 232 of the Companies Act, 2013, seeking approval for the merger between the two entities and their respective shareholders and creditors.

The hearing follows an order dated July 15, 2026, from the Hon'ble NCLT, Chennai Bench. The company has published newspaper advertisements in Business Standard and Makkal Kural on July 20, 2026, to intimate stakeholders about the scheduled hearing.

Scheme Details

The amalgamation involves Dr. Agarwal's Eye Hospital Limited as the transferor company and Dr. Agarwal's Health Care Limited as the transferee company. The scheme encompasses the respective shareholders and creditors of both entities.

Shareholder and Creditor Participation

Any person desirous of supporting or opposing the petition must send a notice of intention to the advocate of the petitioner companies. The notice, signed by the individual or their advocate, must include the name and address and reach the advocate's office not later than two days before the hearing date.

Those opposing the petition are required to furnish the grounds of opposition or a copy of their affidavit along with the notice. The advocate's office is located at New No. 10, Old No. 28, Shankaralaya, 3rd Cross Street, RK Nagar, RA Puram, Chennai.

A copy of the petition will be made available to any person requiring it upon payment of the prescribed charges. The information is also accessible on the company's website.